Clinical investigator networks at Julius Clinical

Clinical networks are vital to the success of academic and clinical research. Clinical investigators communicate and collaborate directly with peers in the scientific community, contributing to the progress of the study in question. In a clinical research environment, creating, maintaining and managing coordinated research networks delivers concrete benefits. Our clinical investigator networks offer:

  • A strong and committed network of academic leaders and investigators around the world in a range of therapeutic areas
  • Partnerships with key medical centres, academic leaders and investigators to ensure the commitment and adherence of local clinicians to study guidelines
  • Access to sites and suitable patients for clinical trials
  • A peer-to-peer leadership model: enhanced recruitment and retention through the leadership provided by the investigators in our networks.

Our networks


We are proud partner of TRICALS. TRICALS is the largest research initiative to find a cure for ALS to date. 40 top research centres in 14 countries have joined hands with patient organisations and fundraisers to reach our one goal: find effective treatments for ALS.

Click here for more information about TRICALS.


ReSViNET is a global network of experts in the field of Respiratory Syncytial Virus (RSV) infections. Skilled recruiters, they have designed and completed multiple RSV trials. ReSViNET has 17 board members representing more than 100 trial sites in 13 countries. These sites are academic hospitals with years of experience in clinical research. This enables fast and high-quality recruitment with an above average retention rate. Because RSV is a cyclical illness, the ReSViNET global network ensures that trials can be conducted throughout the year, following the outbreak of the disease across continents and hemispheres. ReSViNET experts and investigator sites are therefore located around the world, making it a truly international network.

Our clinical network model brings scientific leadership, deep RSV knowledge and wide trial experience to the various levels of these complex clinical trials. This benefits trial outcomes by offering academic leadership and enabling us to extend our RSV knowledge and experience to the site study team. We deliver our services for both clinical trials in paediatrics, and trials in older adults. The ReSViNET clinical research network falls within our infectious diseases and immunology therapeutic area specialism.

Visit the ReSViNET website to learn more about this scientific network.

Primary Care Research Network (PCRN)

Julius Clinical has a department that focuses entirely on research within primary care: the Primary Care Research Network (PCRN). The PCRN is a group of motivated and qualified general practitioners, pharmacists, practice assistants and practice nurses with an interest in conducting high-quality clinical scientific research.

General practitioners handle the majority of medical issues in the Netherlands. The excellent organisation of primary care in the country provides numerous opportunities for clinical research. The PCRN comprises nearly 1000 medical professionals who are involved in clinical drug research, coordinated in the primary care setting by Julius Clinical. We also work closely with the Julius Center for Health Sciences and Primary Care at UMC Utrecht. The PCRN clinical research network works across our three  therapeutic area specialisms.

Click here to learn more about this network.

NASH Clinical

NASH Clinical is a Julius Clinical academic research organisation (ARO), a global network of clinicians and investigators that operates as a fully independent research network. Its mission is to reduce problems arising from non-alcoholic steatohepatitis (NASH) worldwide. The founding members, who share many values professionally, already knew each other through research, education or other network activities.

The participating clinicians are endocrinologists, gastroenterologists, diabetologists and general internists. There have connections with a dozen hospitals in the Netherlands and many more hospitals worldwide. The CardioClinical research network falls within our cardiovascular therapeutic area specialism.

Visit the NASH Clinical website to learn more about this network.


CardioClinical is a large global network of cardiologists and researchers who focus on developing novel therapies for cardiovascular diseases – mainly lipid-lowering cardiovascular intervention trials, stroke prevention and heart failure. The network is based on strong and long collaborations with cardiologists from different hospitals. CardioClinical comprises 1000+ hospitals in 32 countries, so providing sites and expertise around the world. The network has been involved in various large-scale randomised intervention trials into the prevention and treatment of cardiovascular disease and its staff are experienced in performing such trials. This facilitates fast and high-quality recruitment and above-average retention rates.

Everyone involved in the CardioClinical scientific network share a common goal: reducing the burden of cardiovascular disease, which has remained the leading cause of death globally for the last 15 years. Through CardioClinical, Julius Clinical can access pioneering expertise and capabilities for cardiovascular research and trials. This, in turn, supports the pharmaceutical industry in developing drugs and running trials that have the greatest impact on the cardiological health of millions of people around the world. The CardioClinical research network falls within our cardiovascular therapeutic area specialism.


Access to healthcare in sub-Saharan countries remains a challenge, resulting in profound inequities in health in the region. Challenges to effective health services and interventions include geographical, physical financial and/or cultural barriers. Sub-Sahara has one of the highest neonatal and maternal mortality and morbidity rates in the world, and almost 70% of all HIV/Aids cases are found here. Clearly, support for the region is desperately needed.

In response, Julius Clinical and Julius Global Health (part of the University Medical Center Utrecht) have created AfricaClinical, a network of local clinical investigators and institutes who are committed to improving healthcare and the health of the sub-Saharan population.

The network consists of 40 local investigators from 20 countries with a trial network of over 100 sites. These investigators and sites share many years of experience in research and performing clinical trials in the fields of infectious diseases, metabolic diseases and cardiovascular diseases, and they have access to a substantial number of patients, enabling fast and high-quality recruitment with a good retention rate.

We are involved in the European Developing Countries Clinical Trials Partnership (EDCTP) – TDR Clinical Research and Development Fellowship as a host organisation. The AfricaClinical research network works across our infectious diseases therapeutic area specialism.

Visit the AfricaClinical website to learn more about this network.